Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
afuzosin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| afuzosin | DRUG | - |
Inclusion Criteria: * Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography * Suffering for at least 6 months from lower urinary tract symptoms related to BPH * An I-PSS total score ≥ 13 * Out patient Exclusion Criteria: * Patients previously treated with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | - | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | N/A | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | N/A | Undisclosed |
| Profound Medical Corp | PROF | 1 | - | Undisclosed |
Afuzosin is used for the treatment of Benign Prostatic Hyperplasia (BPH), a condition in which the prostate gland is enlarged. It is being developed as a therapeutic option for patients with this urological condition.
Afuzosin is being developed by Sanofi, a multinational pharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY.
Afuzosin is in Phase 3 of clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial for afuzosin has been completed.
Afuzosin has been studied in one clinical trial with the identifier NCT00347061. This trial, titled "Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH," was a Phase 3 study conducted in Japan. The trial enrolled 148 male patients aged 50 years and older.
Yes, afuzosin is also known as alfuzosin. In the clinical trial NCT00347061, the drug is referred to as SL77.0499-10 (Alfuzosin). This alternative name is used in the context of the study.